VRTX · News · 20260821N

Market Demand Trends

VERTEX PHARMACEUTICALS INC / MA · 2026-08-21 · Importance 54 · Surprise 40

Vertex reported strong demand for its cystic fibrosis treatments, which remains the primary driver of commercial performance. Demand is also expanding for CASGEVY in sickle cell disease and beta thalassemia, as well as JOURNAVX in acute pain. Reported quarterly revenue increased 12.5% year over year to $3.33 billion, indicating continued growth across the product portfolio while cystic fibrosis remains a significant concentration.

Key facts

• Analysts maintain a "Moderate Buy" consensus rating on Vertex with an average price target of $563.50. source
• Vertex's stock closed at $548.05 on Friday after a 1.44% rally and was 1.02% below its 52-week high. source
• Institutional investors own 90.96% of Vertex Pharmaceuticals. source